10x Genomics (TXG) Expected to Announce Quarterly Earnings on Thursday

10x Genomics (NASDAQ:TXG) will likely be issuing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $146.3810 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.06. The firm had revenue of $166.03 million during the quarter, compared to analyst estimates of $160.35 million. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.10x Genomics’s revenue was up .6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.40) EPS. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

Shares of NASDAQ:TXG traded up $0.36 during midday trading on Tuesday, hitting $22.01. The company had a trading volume of 3,045,082 shares, compared to its average volume of 2,571,539. The company has a market cap of $2.81 billion, a price-to-earnings ratio of -62.89 and a beta of 2.05. 10x Genomics has a 12-month low of $7.72 and a 12-month high of $26.44. The company has a fifty day moving average of $21.32 and a two-hundred day moving average of $18.74.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Leerink Partners reduced their price objective on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating for the company in a research note on Tuesday, January 27th. UBS Group upped their price objective on 10x Genomics from $14.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday, February 20th. Stifel Nicolaus upped their price objective on 10x Genomics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Barclays upped their price objective on 10x Genomics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 10x Genomics in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, 10x Genomics has an average rating of “Hold” and an average target price of $20.82.

Insiders Place Their Bets

In other 10x Genomics news, CEO Serge Saxonov sold 5,000 shares of the stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $24.56, for a total value of $122,800.00. Following the completion of the sale, the chief executive officer owned 1,167,273 shares in the company, valued at approximately $28,668,224.88. This represents a 0.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Benjamin J. Hindson sold 7,826 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $18.58, for a total value of $145,407.08. Following the completion of the sale, the insider owned 424,779 shares of the company’s stock, valued at $7,892,393.82. The trade was a 1.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 46,426 shares of company stock worth $902,695. Corporate insiders own 8.84% of the company’s stock.

Institutional Investors Weigh In On 10x Genomics

Institutional investors have recently bought and sold shares of the business. Cibc World Market Inc. grew its position in shares of 10x Genomics by 2.2% during the fourth quarter. Cibc World Market Inc. now owns 63,849 shares of the company’s stock valued at $1,041,000 after purchasing an additional 1,385 shares in the last quarter. New York State Common Retirement Fund grew its position in shares of 10x Genomics by 4.4% during the fourth quarter. New York State Common Retirement Fund now owns 36,017 shares of the company’s stock valued at $587,000 after purchasing an additional 1,533 shares in the last quarter. Creative Planning grew its position in shares of 10x Genomics by 3.0% during the third quarter. Creative Planning now owns 56,874 shares of the company’s stock valued at $665,000 after purchasing an additional 1,637 shares in the last quarter. Van ECK Associates Corp grew its position in shares of 10x Genomics by 85.9% during the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock valued at $60,000 after purchasing an additional 1,695 shares in the last quarter. Finally, Martingale Asset Management L P grew its position in shares of 10x Genomics by 3.5% during the fourth quarter. Martingale Asset Management L P now owns 89,006 shares of the company’s stock valued at $1,452,000 after purchasing an additional 3,003 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.